Announcement
08 Jan 2026
In January 2026, Johnson & Johnson announced reaching an agreement with the United States government to implement most-favoured-nation drug pricing for American patients.
Source
Number of interventions
3
0 certainly harmful
3 likely harmful
0 liberalising
Implementation date
No implementation date
Revocation date:
No revocation date
Recent update from 05 Apr 2026:
On 8 January 2026, Johnson & Johnson announced reaching an agreement with the U.S. Administration. Under the agreement, Johnson & Johnson's pharmaceutical products will be exempt from tarif...
Recent update from 05 Apr 2026:
On 8 January 2026, Johnson & Johnson announced reaching an agreement with the U.S. Administration. Under the agreement, Johnson & Johnson's pharmaceutical products will be exempt from poten...
Recent update from 05 Apr 2026:
On 8 January 2026, Johnson & Johnson announced reaching an agreement with the U.S. Administration providing the company's pharmaceutical products an exemption from potential Section 232 tariffs...
See all
This state act is not part of any Thread yet.